Evaxion Biotech AS (EVAX) — Financial Flexibility Index
Evaxion Biotech AS (EVAX) has a Financial Flexibility Index of -0.58x as of December 2025. Free cash flow of $-6.63 Million (operating CF $-6.65 Million minus capex $11.03K) represents -1% of total liabilities ($11.37 Million). Check EVAX PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Evaxion Biotech AS Financial Flexibility Index (2018–2025)
Historical Financial Flexibility Index trend for Evaxion Biotech AS across 8 annual periods. See EVAX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Evaxion Biotech AS (2018–2025)
Year-by-year free cash flow to debt coverage for Evaxion Biotech AS. For the full company profile including market capitalisation, see Evaxion Biotech AS (EVAX) total market value.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.58x | $-6.63 Million | $-6.65 Million | $11.37 Million | ▲ +36.2% |
| 2024 | -0.92x | $-12.94 Million | $-12.94 Million | $14.14 Million | ▲ +8.4% |
| 2023 | -1.00x | $-17.60 Million | $-17.69 Million | $17.62 Million | ▲ +46.2% |
| 2022 | -1.86x | $-25.48 Million | $-25.77 Million | $13.72 Million | ▲ +30.3% |
| 2021 | -2.66x | $-20.57 Million | $-21.93 Million | $7.73 Million | ▼ -8.9% |
| 2020 | -2.44x | $-12.04 Million | $-12.44 Million | $4.93 Million | ▲ +39.6% |
| 2019 | -4.04x | $-6.96 Million | $-7.03 Million | $1.72 Million | ▼ -1825.3% |
| 2018 | -0.21x | $-1.98 Million | $-1.99 Million | $9.44 Million | — |